New Meta-Analysis Supports Targeted Vitiligo Therapies
Explore the promising role of JAK inhibitors in vitiligo management, highlighting efficacy, safety, and potential combination therapies for enhanced results.
Related Articles
Advancements in Breast Cancer Treatment | PBCC 2025
Register now for the 5th Annual Perspectives in Breast Cancer Care, September 12-13, 2025 and explore groundbreaking advancements in breast cancer treatment. Stay informed with…
Recludix Unveils First BTK SH2 Domain Inhibitor
Recludix Pharma unveils a groundbreaking BTK SH2 inhibitor, showcasing superior selectivity and efficacy for chronic spontaneous urticaria treatment at SID 2025.
Clinuvel Completes Enrollment in Phase III Afamelanotide Vitiligo Trial
Clinuvel’s phase III trial CUV105 enrolls 200 patients, exploring afamelanotide as a promising systemic treatment for vitiligo.
Laser and Energy-Based Device Safety in Skin of Color: A Stepwise Framework
On the first day of Dermatology Week, Dr Vincent Richer, a Vancouver-based dermatologist, offered a practical framework for minimizing post-inflammatory pigment alteration.
Prolonged Use of Oral Corticosteroids in Atopic Dermatitis Linked to Increased Cardiovascular Risks
Extended oral corticosteroid therapy in patients with atopic dermatitis significantly increases cardiovascular and thrombotic risks, urging careful treatment evaluations.
Botanical-Based Nutraceutical Improves Acne
Discover how a novel nutraceutical significantly improves mild to moderate acne in a 12-week clinical trial, offering a holistic approach to skin health.
Toughness Is More Than Skin-Deep: Who Cries and Who Doesn’t in a Dermatology Clinic
Hershel Dobkin, MD, FAAD, discusses the surprising truth about toughness in dermatology, unexpected patient reactions, and the emotional depth behind appearances.
The Role of Formulation in Benzene Formation in Benzoyl Peroxide Products
This quality improvement study examines the effects of formulation on benzene levels detected in over-the-counter benzoyl peroxide products.
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body
This randomized clinical trial assesses the safety and efficacy of roflumilast foam, 0.3%, in patients with psoriasis of the scalp and body.